Liquidia Technologies, Inc.

Company Summary

Liquidia is a late-stage biopharmaceutical company focused on the development and commercialization of human therapeutics using our proprietary PRINT technology to transform the lives of patients.

Transaction Overview

In September 2017, the Company’s Board of Directors and principal investors (including representatives from Bill & Melinda Gates Foundation, Canaan Partners, Morningside, NEA, GSK, and Pappas Ventures) approved the Singapore Financing Pathway.

‍

Significance of the Transaction

Healthios Role

If you would like to learn more information about this transaction contact us below.

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

Private Placement

Liquidia Technologies, Inc.

Has completed an IPO stable financing $9,800,000

The undersigned acted as financial advisor to Liquidia